Elan Corporation Plc has announced the appointment of Hans Peter Hasler as its chief operating officer, effective 1 October 2012. Mr Hasler is currently a non-executive director of the company and upon assuming his new role, he will retire from the board. From 2001 to 2009, Mr Hasler was an executive of Biogen Idec, most recently as COO responsible for all commercial operations. Biogen Idec is Elan’s marketing partner for the multiple sclerosis drug Tysabri (natalizumab).
Elan announced the appointment on 21 September 2012.
Copyright 2012 Evernow Publishing Ltd